MX2023009221A - Metodos de descubrimiento de anticuerpos no terminales y ensayos unicelulares. - Google Patents

Metodos de descubrimiento de anticuerpos no terminales y ensayos unicelulares.

Info

Publication number
MX2023009221A
MX2023009221A MX2023009221A MX2023009221A MX2023009221A MX 2023009221 A MX2023009221 A MX 2023009221A MX 2023009221 A MX2023009221 A MX 2023009221A MX 2023009221 A MX2023009221 A MX 2023009221A MX 2023009221 A MX2023009221 A MX 2023009221A
Authority
MX
Mexico
Prior art keywords
select antibodies
human animal
ascs
production
single cell
Prior art date
Application number
MX2023009221A
Other languages
English (en)
Inventor
Aaron George Winters
Christopher Murawsky
Karyn E Mcfadden
Brian M Chan
Daniel Santos
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023009221A publication Critical patent/MX2023009221A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se proporcionan en el presente documento métodos de monitorización de la producción de anticuerpos selectos en un animal no humano, que comprenden (a) inmunizar a un animal no humano con un inmunógeno; (b) obtener una muestra de sangre que comprenda células secretoras de anticuerpos (ASC) de dicho animal no humano; y (c) ensayar individualmente, las ASC presentes en la muestra de sangre, o una fracción de la misma, para la producción de anticuerpos selectos. También se proporcionan métodos para guiar la producción de anticuerpos en un animal no humano para la producción de anticuerpos selectos. En realizaciones a modo de ejemplo, el método comprende la realización de un ciclo de (a) a (c), como se ha indicado anteriormente, y la repetición del ciclo cuando el porcentaje de las ASC productoras de anticuerpos selectos está por debajo de un umbral. En varios aspectos, el ciclo se repite hasta que el porcentaje de las ASC productoras de anticuerpos selectos, según lo ensayado está en o por encima de un umbral. En el presente documento se proporcionan además ensayos unicelulares.
MX2023009221A 2021-02-05 2022-02-04 Metodos de descubrimiento de anticuerpos no terminales y ensayos unicelulares. MX2023009221A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163146135P 2021-02-05 2021-02-05
PCT/US2022/015279 WO2022170071A2 (en) 2021-02-05 2022-02-04 Non-terminal antibody discovery methods and single cell assays

Publications (1)

Publication Number Publication Date
MX2023009221A true MX2023009221A (es) 2023-09-11

Family

ID=80735618

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023009221A MX2023009221A (es) 2021-02-05 2022-02-04 Metodos de descubrimiento de anticuerpos no terminales y ensayos unicelulares.
MX2023009206A MX2023009206A (es) 2021-02-05 2022-02-04 Generacion mejorada de hibridomas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023009206A MX2023009206A (es) 2021-02-05 2022-02-04 Generacion mejorada de hibridomas.

Country Status (10)

Country Link
US (2) US20240103009A1 (es)
EP (2) EP4288524A2 (es)
JP (2) JP2024507457A (es)
KR (2) KR20230141840A (es)
CN (2) CN117098839A (es)
AU (2) AU2022216617A1 (es)
CA (2) CA3210331A1 (es)
IL (2) IL304826A (es)
MX (2) MX2023009221A (es)
WO (2) WO2022170071A2 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933435A (en) 1989-04-05 1990-06-12 Bioprobe International Antibody purification process
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
EP1543039B1 (en) * 2002-08-12 2011-07-13 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes
US20100221755A1 (en) * 2007-06-15 2010-09-02 University Of Rochester Use of antibody secreting cell elispot to assess antibody responses following antigen exposure
ES2548014T3 (es) * 2008-07-16 2015-10-13 Institute For Research In Biomedicine Anticuerpos neutralizantes del citomegalovirus humano y uso de los mismos
WO2010034103A1 (en) * 2008-09-23 2010-04-01 Héma-Québec Method for polyclonal immunoglobulin g production by human b cells
WO2014093786A1 (en) * 2012-12-14 2014-06-19 Abbvie, Inc. Methods for increasing the efficiency of hybridoma generation
TW202122107A (zh) * 2019-08-30 2021-06-16 美商建南德克公司 開發用於治療性抗體研發之有效的融合瘤平台

Also Published As

Publication number Publication date
EP4288450A1 (en) 2023-12-13
CA3210331A1 (en) 2022-08-11
CN117098839A (zh) 2023-11-21
WO2022170071A3 (en) 2022-09-29
CN117120468A (zh) 2023-11-24
US20240103009A1 (en) 2024-03-28
WO2022170071A2 (en) 2022-08-11
AU2022216617A9 (en) 2024-09-19
US20240094218A1 (en) 2024-03-21
AU2022218181A1 (en) 2023-08-17
IL304825A (en) 2023-09-01
AU2022218181A9 (en) 2024-05-02
KR20230141851A (ko) 2023-10-10
KR20230141840A (ko) 2023-10-10
CA3210091A1 (en) 2022-08-11
WO2022170074A1 (en) 2022-08-11
IL304826A (en) 2023-09-01
MX2023009206A (es) 2023-09-08
JP2024509697A (ja) 2024-03-05
AU2022216617A1 (en) 2023-08-17
JP2024507457A (ja) 2024-02-20
EP4288524A2 (en) 2023-12-13

Similar Documents

Publication Publication Date Title
WO2011002727A9 (en) Methods of producing humanized non-human mammals
MX2010002044A (es) Metodos para produccion recombinante de anticuerpos anti-virus sincitial respiratorio (anti-rsv).
RU2014117161A (ru) Композиции и способы испытаний на токсикогенность
ATE556091T2 (de) Monoklonale antikörperproduktion durch ebv transformation von b-zellen
CN104152357A (zh) 同时提高小球藻中叶绿素和蛋白质含量的高密度培养方法
CN109665596A (zh) 同时优化反渗透膜去除沼液cod和氨氮效果的方法
BR112022003852A2 (pt) Métodos de preparação de células t para terapia de células t
MX2023009221A (es) Metodos de descubrimiento de anticuerpos no terminales y ensayos unicelulares.
RU2018130530A (ru) Способ получения активного фактора роста гепатоцитов (hgf)
DE60319599D1 (de) Verfahren zur differenzierung einer mesenchym-stammzelle zu einer nervenzelle sowie die nervenzelle eine neurodegenerative krankheit
Ishmayana et al. Fermentation performance of the yeast Saccharomyces cerevisiae in media with high sugar concentration
MY197429A (en) Afucosylated antibodies and manufacture thereof
AT517476A4 (de) Zellkulturstatusbestimmung
CN103898063B (zh) 半固体筛选培养基以及杂交瘤细胞的筛选方法
Liu et al. Kinetic modeling for redox potential-controlled repeated batch ethanol fermentation using flocculating yeast
Liu et al. Optimization of growth conditions toward two‐stage cultivation for lipid production of chlorella vulgaris
白龙 et al. First isolation and identification of cold adaptive yeast Curvibasidium rogersii from Usnea lichen and genome-based studies of its biological properties
WO2009129654A8 (zh) 一种控制发酵过程的方法和装置
Atelge Co-digestion of orange pulp and cattle manure with different c/n ratios and a new modeling of biogas production
CN107841495B (zh) 利用光合放氧电子分离快速筛检核诱变固碳藻株的方法
CN105925487A (zh) 提高微藻细胞含糖量的培养方法
Mikami et al. Enhancing in vitro antibody production rate per cell by applying mouse peritoneal factors
Mairet et al. Driving species competition in a light-limited chemostat
Ljunggren Kinetic analysis and modeling of enzymatic hydrolysis and SSF
Gramer et al. Selection and isolation of cells for optimal growth in hollow fiber bioreactors